Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy

Once melanomas have progressed with acquired resistance to mitogen-activated protein kinase (MAPK)-targeted therapy, mutational heterogeneity presents a major challenge. We therefore examined the therapy phase before acquired resistance had developed and discovered the melanoma survival oncogene MIT...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Cell
Main Authors: Smith, Michael P., Brunton, Holly, Rowling, Emily J., Ferguson, Jennifer, Arozarena, Imanol, Miskolczi, Zsofia, Lee, Jessica L., Girotti, Maria R., Marais, Richard, Levesque, Mitchell P., Dummer, Reinhard, Frederick, Dennie T., Flaherty, Keith T., Cooper, Zachary A., Wargo, Jennifer A., Wellbrock, Claudia
Formato: Artigo
Idioma:Inglês
Publicado em: Cell Press 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4796027/
https://ncbi.nlm.nih.gov/pubmed/26977879
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2016.02.003
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados